Klinik Araştırma

Comparison of Comorbid Diseases Between Early-Onset and Late- Onset Systemic Lupus Erythematosus; A Single Center Retrospective Experience

Cilt: 7 Sayı: 3 9 Eylül 2025
PDF İndir
EN

Comparison of Comorbid Diseases Between Early-Onset and Late- Onset Systemic Lupus Erythematosus; A Single Center Retrospective Experience

Abstract

Aim: To examine the comorbidity profile of patients with systemic lupus erythematosus (SLE) and to evaluate differences in comorbidity burden between late-onset and early-onset SLE patients. Material and Method: We retrospectively analyzed SLE patients who presented to the tertiary rheumatology clinic between February 2024 and February 2025. Patients were categorized by age at diagnosis into three groups: childhood-onset (<18 years), adult-onset (18–49 years), and late-onset (≥50 years). Comorbidities were systematically documented and compared across groups. Results: 284 SLE patients were included, with a mean age at diagnosis of 37.2 (±11.2) years; 83.8% were female. Arterial hypertension was the most common comorbidity (23.9%). Of the patients, 27 (7.1%) had childhood-onset SLE, 176 (61.9%) had adult-onset, and 81 (28.5%) had late-onset SLE. Arterial hypertension (46.9% vs. 15.9% and 7.4%, p₁=0.004, p₂=0.0021) and osteoporosis (22.2% vs. 4.5% and 3.7%, p₁=0.014, p₂=0.032) were more common in the late-onset SLE. The childhood SLE had higher rate of autoimmune thyroid diseases (22.2%), although differences between groups were not statistically significant. Conclusion: Comorbid conditions, such as arterial hypertension and osteoporosis are more prevalent in late-onset SLE patients. These comorbidities may complicate disease management and should be considered as part of a comprehensive treatment strategy to optimize outcomes in daily clinical practice.

Keywords

Etik Beyan

This study received the necessary ethical approval from the Ethics Committee of Gülhane Training and Research Hospital (Date: 06 May 2025; Decision number: 2025/272).

Kaynakça

  1. Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin North Am. 2013;57:631-55.
  2. Uzun GS, Abida R, Isenberg DA. Advances in systemic lupus erythematosus. Medicine. 2024;52:737-45.
  3. Gamal SM, Mokbel A, Niazy MH, et al. Comorbidities among Egyptian systemic lupus erythematosus: The COMOSLE-EGYPT study. Chronic Illn. 2023;19:791-803.
  4. Reese T, Dickson AL, Shuey MM, et al. Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden. Lupus. 2019;28:954-60.
  5. Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. Semin Arthritis Rheum. 2016;45:604-10.
  6. Gergianaki I, Garantziotis P, Adamichou C, et al. High comorbidity burden in patients with SLE: data from the community-based lupus registry of crete. J Clin Med. 2021;10:998.
  7. Akca UK, Ayaz NA. Comorbidities of antiphospholipid syndrome and systemic lupus erythematosus in children. Curr Rheumatol Rep. 2020;22:21.
  8. Yu C-Y, Kuo C-F, Chou I-J, et al. Comorbidities of systemic lupus erythematosus prior to and following diagnosis in different age-at-onset groups. Lupus. 2022;31:963-73.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Romatoloji ve Artrit

Bölüm

Klinik Araştırma

Yayımlanma Tarihi

9 Eylül 2025

Gönderilme Tarihi

4 Haziran 2025

Kabul Tarihi

30 Haziran 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 7 Sayı: 3

Kaynak Göster

AMA
1.Sandal Uzun G, Tekgöz E, Çimen Güneş E, vd. Comparison of Comorbid Diseases Between Early-Onset and Late- Onset Systemic Lupus Erythematosus; A Single Center Retrospective Experience. Med Records. 2025;7(3):780-3. https://izlik.org/JA87UU37ME